PUNE, India, April 25, 2017 /PRNewswire/ --
The latest pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Browse 28 Tables and 11 Figures, 15 Major Company Profiles, spread across 108 pages available at http://www.reportsnreports.com/reports/958319-fragile-x-syndrome-pipeline-review-h1-2017.html.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The Fragile X Syndrome - Drug Profiles are ACT-01, AMO-01, ANAVEX-273, Bryostatin-1, cannabidiol and cercosporamide.
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile: flindokalner, gaboxadol, ganaxolone, JRP-655, NNZ-2591, NST-0076, SAGE-217 and SGE-872
Drug Profile Listed for Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome; Small Molecule to Activate FMRP for Fragile X Syndrome; Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome; Small Molecules to Activate Slack Channels for Fragile X Syndrome; Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome; Small Molecules to Block Kv3.1 for Fragile X Syndrome; Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - SRT-278, TC-2153 and trofinetide.
Order a Copy of Report at http://www.reportsnreports.com/purchase.aspx?name=958319.
The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. Companies Involved in Therapeutics Development are Aelis Farma SAS, AMO Pharma Ltd, Anavex Life Sciences Corp, Confluence Pharmaceuticals LLC, DRI Biosciences Corp, Eli Lilly and Company, Fulcrum Therapeutics Inc, GlaxoSmithKline Plc, GW Pharmaceuticals Plc, Marinus Pharmaceuticals Inc, Neuren Pharmaceuticals Ltd, Neuron Biopharma SA, Ovid Therapeutics Inc, Sage Therapeutics Inc and Zynerba Pharmaceuticals Inc.
Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) Other New Reports:
Pancreatitis - Pipeline Review, H1 2017
Contact Dermatitis - Pipeline Review, H1 2017
Actinic (Solar) Keratosis - Pipeline Review, H1 2017
Explore More Reports on Pharmaceuticals Market at http://www.reportsnreports.com/market-research/pharmaceuticals/.
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact: Ritesh Tiwari 2nd Floor, Metropole Building Next to Inox Theatre Bund Garden Road, Pune - 411013 Maharashtra, India +1-888-391-5441 [email protected]
Advertisement
The latest pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Advertisement
Browse 28 Tables and 11 Figures, 15 Major Company Profiles, spread across 108 pages available at http://www.reportsnreports.com/reports/958319-fragile-x-syndrome-pipeline-review-h1-2017.html.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The Fragile X Syndrome - Drug Profiles are ACT-01, AMO-01, ANAVEX-273, Bryostatin-1, cannabidiol and cercosporamide.
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile: flindokalner, gaboxadol, ganaxolone, JRP-655, NNZ-2591, NST-0076, SAGE-217 and SGE-872
Drug Profile Listed for Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome; Small Molecule to Activate FMRP for Fragile X Syndrome; Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome; Small Molecules to Activate Slack Channels for Fragile X Syndrome; Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome; Small Molecules to Block Kv3.1 for Fragile X Syndrome; Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - SRT-278, TC-2153 and trofinetide.
Order a Copy of Report at http://www.reportsnreports.com/purchase.aspx?name=958319.
The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. Companies Involved in Therapeutics Development are Aelis Farma SAS, AMO Pharma Ltd, Anavex Life Sciences Corp, Confluence Pharmaceuticals LLC, DRI Biosciences Corp, Eli Lilly and Company, Fulcrum Therapeutics Inc, GlaxoSmithKline Plc, GW Pharmaceuticals Plc, Marinus Pharmaceuticals Inc, Neuren Pharmaceuticals Ltd, Neuron Biopharma SA, Ovid Therapeutics Inc, Sage Therapeutics Inc and Zynerba Pharmaceuticals Inc.
Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) Other New Reports:
Pancreatitis - Pipeline Review, H1 2017
Contact Dermatitis - Pipeline Review, H1 2017
Actinic (Solar) Keratosis - Pipeline Review, H1 2017
Explore More Reports on Pharmaceuticals Market at http://www.reportsnreports.com/market-research/pharmaceuticals/.
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact: Ritesh Tiwari 2nd Floor, Metropole Building Next to Inox Theatre Bund Garden Road, Pune - 411013 Maharashtra, India +1-888-391-5441 [email protected]
Connect with Us:
LinkedIn:
http://www.linkedin.com/company/reportsnreports
RSS/Feeds:
http://www.reportsnreports.com/feed/l-latestreports.xml
SOURCE ReportsnReports
